or Try an Advanced Search...

    Technical Analysis for TH - Theratechnologies Inc.

    Grade Last Price % Change Price Change
    C 2.260 11.88% 0.240
    TH closed up 11.88 percent on Tuesday, November 28, 2023, on 82 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical TH trend table...
    Date Alert Name Type % Chg
    Crossed Above 50 DMA Bullish 0.00%
    180 Bullish Setup Bullish Swing Setup 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Fell Below 50 DMA Bearish 11.88%
    Stochastic Sell Signal Bearish 11.88%
    Expansion Pivot Sell Setup Bearish Swing Setup 11.88%
    Upper Bollinger Band Walk Strength 11.88%
    Wide Bands Range Expansion 11.88%
    Older End-of-Day Signals for TH ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    50 DMA Resistance about 19 hours ago
    Possible Inside Day about 19 hours ago
    Rose Above 50 DMA about 20 hours ago
    Up 5% about 20 hours ago
    Up 3% about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    TH Chart by TradingView
    Basic chart:

    Profile

    Theratechnologies Inc. Description

    Theratechnologies Inc. is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition Company.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Health Pharma Pharmaceutical Drug Medical Specialties IPO Organ Systems Hiv Immunology Infection Rift Antivirals

    Is TH a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 24 Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
    Oct 31 Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
    Oct 26 Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
    Oct 25 Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
    Oct 24 Theratechnologies Announces Operational Update
    Oct 19 Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
    Oct 16 Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon
    Oct 13 Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
    Oct 13 Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study
    Oct 12 Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
    See more TH news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.45
    52 Week Low 0.73
    Average Volume 81,165
    200-Day Moving Average 1.584
    50-Day Moving Average 2.136
    20-Day Moving Average 1.825
    10-Day Moving Average 2.010
    Average True Range 0.231
    RSI (14) 59.02
    ADX 16.98
    +DI 28.333
    -DI 22.437
    Chandelier Exit (Long, 3 ATRs) 1.768
    Chandelier Exit (Short, 3 ATRs) 1.962
    Upper Bollinger Bands 2.349
    Lower Bollinger Band 1.300
    Percent B (%b) 0.92
    BandWidth 57.506
    MACD Line 0.060
    MACD Signal Line -0.021
    MACD Histogram 0.0813
    Fundamentals Value
    Market Cap 174.05 Million
    Num Shares 77 Million
    EPS -0.09
    Price-to-Earnings (P/E) Ratio -25.39
    Price-to-Sales 2.87
    Price-to-Book 21.32
    PEG Ratio -199.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.740
    Resistance 3 (R3) 2.690 2.480 2.660
    Resistance 2 (R2) 2.480 2.358 2.505 2.633
    Resistance 1 (R1) 2.370 2.282 2.425 2.420 2.607
    Pivot Point 2.160 2.160 2.188 2.185 2.160
    Support 1 (S1) 2.050 2.038 2.105 2.100 1.913
    Support 2 (S2) 1.840 1.962 1.865 1.887
    Support 3 (S3) 1.730 1.840 1.860
    Support 4 (S4) 1.780